[1]
D'Amico A., Mercuri E., D Tiziano F., et al.: Spinal muscular atrophy.
Orphanet Journal of Rare Diseases 2011; 6: 71.
[2]
Zerres K., Rudnik-Schöneborn S., Forrest E., et al.: A collaborative study
on the natural history of childhood and juvenile onset proximal spinal
muscular atrophy (type II and III SMA): 569 patients. Journal of the
Neurological Sciences 1997; 146: 67-72.
[3]
Saniewska E., Saniewska N.: Wiedza pacjentów obciążonych rdzeniowym
zanikiem mięśni (SMA) oraz ich opiekunów na temat choroby. PRYMAT,
Białystok 2019.
[4]
Tomczyński J., Werner B., Bartosiak I.: Fizjoterapia dzieci z rdzeniowym
zanikiem mięśni. Pediatria Polska 2011; 86: 82-85.
[5]
Małachowska-Sobieska M., Demczuk-Włodarczyk E., Wronecki K., et al.:
Orteza dynamiczna Dunag 02. Fizjoterapia 2013; 21: 45-61.
[6]
Dunaway S., Montes J., McDermott M., et al.: Physical therapy services
received by individuals with spinal muscular atrophy (SMA). JPRM
2016; 9: 35-44.
[7]
Adler S., Beckers D., Buck M.: PNF in Practice. An Illustrated Guide.
Springer-Verlag Berlin Heidelberg, Heidelberg 2008.
[8]
Darras B. T., Farrar M. A., Mercuri E., et al.: An Integrated Safety Analysis
of Infants and Children with Symptomatic Spinal Muscular Atrophy
(SMA) Treated with Nusinersen in Seven Clinical Trials. CNS Drugs
2019; 33: 919-931.
[9]
Grędowska E., Modrzejewska S., Mazurkiewicz-Bełdzińska M.: Nusinersen
w leczeniu rdzeniowego zaniku mięśni – praca poglądowa. Child
Neurology 2019; 28: 17-21.
[10]
Jędrzejowska M., Kostera-Pruszczyk A.: Rdzeniowy zanik mięśni – nowe
terapie, nowe wyzwania. Child Neurology 2017; 26: 11-17.
[11]
CunhaI M. C. B., Oliveira A. S. B., Labronici R. H. D. D., et al.: Spinal
muscular atrophy type II (intermediary) and III (Kugelberg-Welander):
Evolution of 50 patients with physiotherapy and hydrotherapy in
a swimming pool. Arq. Neuro-Psiquiatr 1996; 54: 402-406.
[12]
Divanoglou A., Tasiemski T., Augutis M., et al.: Active Rehabilitation –
a community peer-based approach for persons with spinal cord injury:
international utilisation of key elements. Spinal Cord 2019; 57: 897-905.
[13]
O’Hagena J. M., Glanzmanb A. M., McDermott M. P., et al.: An expanded
version of the Hammersmith Functional Motor Scale for SMA II and III
patients. Neuromuscular Disorders 2007; 17: 693-697.
[14]
Main M., Kairon H., Mercuri E., et al.: The Hammersmith functional motor
scale for children with spinal muscular atrophy: a scale to test ability
and monitor progress in children with limited ambulation. Eur J Paediatr
Neurol 2003; 7: 155-159.
[15]
Pera M. C., Coratti G., Mercuri E., et al.: Content validity and clinical
meaningfulness of the HFMSE in spinal muscular atrophy. BMC
Neurology 2017; 17: 39.
[16]
Włodarczyk A., Gajewska E.: Przegląd metod oceny funkcjonalnej
analizujących motorykę małą i dużą u chorych z rdzeniowym zanikiem
mięśni. Child Neurology 2019; 28: 23-26.
[17]
Chiriboga C. A., Swoboda K. J., Darras B. T., et al.: Results from a phase
1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular
atrophy. Neurology 2016; 86: 890-897.
Scholar Google
PubMed